What Kromatid does

Kromatid is a Boulder, Colorado-based contract laboratory services company that provides single-cell genomic integrity analysis to cell and gene therapy developers. Founded in 2016, the company operates the KROMASURE Platform, a suite of cytogenetic assays built on proprietary Directional Genomic Hybridization (dGH) technology and advanced fluorescent hybridization methods. The platform enables direct visualization of chromosomal integrity, detection of structural variants as small as approximately 2KB, and transgene integration mapping at single-cell resolution, addressing the limitations of bulk sequencing methods in detecting low-prevalence and complex genomic events (down to 0.1% prevalence). The platform comprises four integrated sub-products: KROMASURE Screen (whole-genome karyotyping with 20kb resolution), KROMASURE KBand (statistical G-Banding across up to 500 cells per batch), KROMASURE InSite (edit site integrity and transgene orientation), and KROMASURE PinPoint (high-throughput transgene integration analysis launched in 2025). The company also offers GLP- and GMP-compliant laboratory services supporting IND submissions and batch release testing.

Kromatid generates revenue through quote-based, project-driven laboratory services sold via direct enterprise engagement with biotech and pharma companies developing CAR-T, CAR-NK, gene therapies, iPSC-derived products, and CRISPR-edited cell therapies. Its go-to-market approach relies on direct scientific consultation rather than channel partners, supported by scientific content marketing, conference participation (notably ASGCT), webinars, white papers, and an active blog. The company emphasizes its singular 100% focus on single-cell cytogenetics as a differentiator from multi-specialty CROs. In August 2025, Kromatid closed an $8 million Series C funding round led by BroadOak Capital Partners, and in June 2026 appointed Matthew Hemstreet as Chief Executive Officer to lead the next phase of commercial scaling.

Name

Kromatid

Legal name

KROMATID, Inc.

Website

https://kromatid.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Kromatid is a Boulder, Colorado-based contract laboratory services company providing single-cell genomic integrity analysis for cell and gene therapy developers. Its KROMASURE Platform uses proprietary directional Genomic Hybridization (dGH) to detect structural variants and map transgene integration at single-cell resolution.

Ownership category

akta.pro rank

Product category

Genomic Integrity Analysis Services

NAICS

Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

akta.pro secondary industries

Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Laboratory Quality & GLP/GCLP Compliance (HLAGAKAK)

Keywords

• Single-cell cytogenetics
• Genomic integrity analysis
• Cell and gene therapy
• Molecular cytogenetics assays
• Chromosomal structural variants

Headquarters

HQ city

Longmont

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Laboratory Services (GLP/GMP): Kromatid generates revenue through providing contract laboratory services for genomic integrity analysis. The company offers GLP-compliant and GMP-compliant testing services supporting the full cell and gene therapy development lifecycle from research through batch release testing. Services are priced quote-based and likely follow a per-project or per-assay pricing model.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Kromatid provides single-cell genomic integrity analysis services and assays for cell and gene therapy developers through its proprietary KROMASURE Platform. The company offers GLP- and GMP-compliant contract laboratory services including karyotyping, edit site integrity assessment, transgene mapping, and G-Banding analysis at single-cell resolution. Services support therapy development from discovery through IND submission and batch release testing.

Product overview

Kromatid offers the KROMASURE Platform as its core product, a comprehensive genomic integrity analysis solution consisting of four integrated sub-products: KROMASURE Screen (high-sensitivity karyotyping for detecting mutations down to 20kb), KROMASURE KBand (genomic integrity G-Banding analyzing up to 500 cells with statistical benchmarking), KROMASURE InSite (dGH-based edit site integrity and transgene mapping for ~2KB resolution), and KROMASURE PinPoint (high-throughput transgene integration analysis for thousands of cells). The platform is complemented by GLP and GMP laboratory services. Together, these solutions provide single-cell genomic analysis across the entire cell and gene therapy development lifecycle from discovery through batch release.

Differentiator

Problem solved

Functional benefit

Products and services

• KROMASURE Platform

Quantifiable outcome

• Detection of structural variants as small as 2KB
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

One partnership is on record.

• National Institute of Standards and Technology (NIST)coreStrategic or Co-development PartnerKromatid collaborates with a public-private-academic consortium including NIST to empower cancer genomics with industry-leading sequencing standards. The company is working with this consortium on the Genome in a Bottle program to develop reference standards for genomic analysis.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• BioReliance (MilliporeSigma): BioReliance, part of MilliporeSigma, provides testing and manufacturing services for cell and gene therapies, including biosafety, viral clearance, and cell line characterization. It is a broad incumbent offering adjacent genomic and biological safety testing that competes for budget within CGT sponsors' release-testing workflows.
• Charles River Laboratories: Charles River offers extensive cell and gene therapy services spanning manufacturing, safety testing, and genetic characterization through its CDMO and biologics testing divisions. It competes with Kromatid for genomic integrity work and brings scale, global footprint, and bundled service contracts.
• Eurofins Genomics: Eurofins Genomics offers a broad portfolio of genomic and molecular biology services, including custom assays, sequencing, and genotyping, with a global laboratory network. It competes for outsourced genomic testing budgets from biotech and academic customers.
• Lonza Cell & Gene Technologies: Lonza is a leading global CDMO with deep cell and gene therapy manufacturing and testing capabilities, including genomic release testing for autologous and allogeneic therapies. It competes with Kromatid at the testing-services level while also serving as a potential channel partner for large sponsors.

Direct peers

• NeoGenomics Laboratories: NeoGenomics is a clinical and research cytogenetics laboratory offering karyotyping, FISH, and molecular cytogenetic services at scale. It is the most direct competitor in cytogenetics services, though its core focus is oncology diagnostics rather than CGT release testing.
• CytoTest: CytoTest develops and supplies FISH probes and cytogenetics reagents used in research and clinical cytogenetics. It is directly comparable as a cytogenetics-focused technology provider and could compete with Kromatid's reagent-side opportunities or partner on assay development.
• Natera: Natera operates a high-throughput CLIA-certified laboratory performing molecular and cytogenetic testing at scale, including cell-free DNA and tumor profiling assays. It is comparable as a specialized, high-sensitivity molecular diagnostics laboratory serving complex genomic testing needs.
• REPROCELL (now part of Rebirthel): REPROCELL provides stem cell, iPSC, and cell-based assay services for drug development and regenerative medicine. It is comparable as a specialized cell and gene therapy services provider with overlap in iPSC characterization, a key application area for Kromatid's KROMASURE platform.

Emerging players

• Bionano Genomics: Bionano's optical genome mapping (OGM) platform is an emerging alternative to traditional cytogenetics for detecting structural variants and copy number changes. It represents a competing single-cell/large-molecule structural variant detection approach that could substitute for dGH in some CGT workflows.
• Personalis: Personalis provides ultra-sensitive genomic sequencing and analysis services, including tumor-informed assays with strong structural variant detection. It is an emerging player in CGT-adjacent genomic testing, particularly for cell therapy bioprocessing and patient monitoring.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@kromatideducation
• LinkedInlinkedin.com/company/kromatid

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds8 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kromatid